FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

FDA Warns 17 Companies for Selling Unapproved Alzheimer’s Drugs

Feb. 22, 2019

FDA Commissioner Scott Gottlieb announced an enforcement action against 17 companies for selling unapproved Alzheimer’s treatments.

The FDA issued 12 warning letters and five advisory letters to firms illegally marketing more than 58 unapproved and misbranded drugs claiming to prevent, treat or cure Alzheimer’s disease, many of them sold as dietary supplements.

Gottlieb said the agency has sent over 40 warning letters in the past five years to companies that illegally sold over 80 products purporting to be Alzheimer’s treatments on websites, social media and in stores.

View today's stories